Researchers still found 'excellent' survival rates for both primary, secondary disease
by Hisfaith on Fri Aug 05, 2011 07:18 PM
my significant other began with a primary head and neck MPNST and it metastisized to his lungs.
i don't have to tell any of you what an angry, aggressive, heartless cancer this is.
two heavy courses of radiation and three separate kinds of chemo didn't work.
what i have seen in my research is that what gives people the best chance is:
1. complete removal of the primary tumor with very, very negative margins
2. resection of any met. tumors as soon as they are found.
if you have the chance to do those things, and it is worth the risk, i encourage you do it, while you still have the chance.
we are beyond that point.
it may not help any of us right now... but...here's an article about Dr. Tina Lev at M.D. Anderson, and her work on malignant peripheral nerve sheath tumors. inspiring reading... http://www.hopefundcancerresearch.org/index.php?option=com_c
you are all in my prayers.
by Hisfaith on Fri Aug 05, 2011 07:19 PM
ps. this was one study i found that had a (so far) good outcome:
Advanced epithelioid malignant peripheral nerve sheath tumor showing complete response to combined surgery and chemotherapy: a case report
Tomohiro Minagawa1, Ryuta Shioya2, Chigusa Sato2, Ryuji Shichinohe1, Go Yasui1, Kohsuke Ishikawa2, and Hiroko Takahashi1
1Department of Plastic and Reconstructive Surgery, Asahikawa-Kosei General Hospital, Asahikawa City, Hokkaido, Japan
2Department of Plastic and Reconstructive Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Department of Plastic and Reconstructive Surgery, Asahikawa Kosei General Hospital, 1 Jo-dohri 24-chome 111, Asahikawa, Hokkaido, Japan, 078-8211
Tel: +81-166-33-7171; Fax: +81-166-33-6075
Malignant peripheral nerve sheath tumor (MPNST) is a rare high-grade soft tissue sarcoma. The epithelioid variant accounts for 5% or less of MPNSTs; the clinical behavior of this variant is unclear. Reports of approximately 40 cases are available in the English literature; however, most reports addressed clinicopathological features rather than therapeutic procedures or clinical courses.
We describe a case of a 62-year-old male with an epithelioid MPNST of the left foot. Multiple lung metastases developed after radical surgery on the primary lesion. The response to adjuvant chemotherapy including doxorubicin and ifosfamide was favorable, and thoracoscopic resection was subsequently performed on the remaining three metastases. No evidence of recurrence or metastasis was observed at the 12-month follow-up after the first operation. Further follow-up and chemotherapy may be required.
Malignant peripheral nerve sheath tumor (MPNST) is a rare malignant soft tissue tumor. Its variants include rhabdomyoblastic, glandular, and epithelioid MPNST . Epithelioid MPNST (EMPNST) accounts for 5% or less of MPNSTs . Approximately 40 cases of EMPNST have been reported in the English literature [2-5]. Most reports address clinicopathological features; however, few reports are available on advanced EMPNST with precise treatment procedures. Here, we report an additional case of EMPNST arising in the foot and involving lung metastases that showed complete response to combined surgery and chemotherapy.
A 62-year old male without neurofibromatosis presented with an enlarging, painful mass in the third web space of his left foot. The lesion was first noticed approximately five years earlier as a nodular lesion that was then diagnosed as an epidermal cyst of the sole at a dermatologic clinic. Neither excision nor biopsy was performed at that time. On examination, there was a firm, round mass measuring 9 × 7 cm in the third web space (Figure 1). The mass was immobile against the surrounding bones and adhered to the overlying skin. Multiple swollen lymph nodes were palpable in the left inguinal region. An open biopsy was performed, which showed proliferation of epithelioid round cells with cellular atypia, indicating probable malignant melanoma. Radiological
examination including fluorodeoxyglucose positron emission tomography showed no evidence of definite distant metastases (Figure 2-a, b). Therefore, surgical treatment was planned under the diagnosis of pT4aN2bM0, stage III-C malignant melanoma according to the American Joint Committee on Cancer classification.
The first operation was performed under general anesthesia. Left inguinal dissection was carried out (Figure 3-a), and an adequately wide excision of the primary tumor with a 30 mm surgical margin (i.e., transmetatarsal amputation) was performed (Figure 3-b). The resultant raw surface of the stump was temporarily covered with an artificial dermis. One week postoperatively, the stump was resurfaced with a free latissimus dorsi musculocutaneous flap with a split-thickness skin graft following histological confirmation of adequate surgical margins (Figure 3-c). Although partial necrosis of the flap was observed postoperatively, application of an additional split-thickness skin graft under local anesthesia led to complete wound healing. The specimen showed nodular growth of the lesion measuring 70 × 43 mm between the dermis and subcutaneous layer without continuity to the epidermis. Histologically, the lesion consisted of two components: proliferation of spindle cells with some differentiation to nerve cells, reminiscent of conventional malignant schwannoma (Figure 4-a), and epithelioid proliferation of round-to-polygonal or rhabdoid cells with hyperchromatic nuclei, reminiscent of malignant melanoma (Figure 4-b, c). Tumor cells stained positive for S-100 protein and negative for HMB45 (Figure 4-d). All dissected lymph nodes were
free of sarcoma. Based on these histological features, the lesion was diagnosed as EMPNST.
Ten weeks after the first operation, computed tomography demonstrated the development of multiple small bilateral lung nodules (Figure 5-a, b). No further evidence of metastasis to other organs was observed. Systemic adjuvant chemotherapy consisting of doxorubicin and ifosfamide was then initiated. Doxorubicin (60 mg/m2) and ifosfamide (7.5 g/m2) with mesna (Uromitexan) were administered. After two courses of the adjuvant therapy, follow-up computed tomography revealed a good response to all abnormal shadows; however, two lesions in segment 8 and one in segment 10 of the left lung field were still observable (Figure 6-a, b). Because these three lesions were located just beneath the pleura, tumors were resected during thoracoscopic surgery five months after the first operation. Histological examination revealed complete necrosis of the tumor cells in one lesion and metastases of EMPNST in the other two lesions. At the 12-month follow-up after radical surgery of the primary tumor, during which time four courses of adjuvant chemotherapy and a thoracic surgery were added, no signs of local recurrence or metastasis were observed (Figure 7-a, b). The patient maintained ambulation without a brace (Figure 8).
Most MPNSTs are generally considered high-grade sarcomas . Approximately
40% of patients developed local recurrence, and the overall five-year survival rate was 34 - 43% [6, 7]. On the other hand, epithelioid variants are rare and are estimated to comprise 5% or fewer of MPNSTs . Thus, biologic behavior and prognosis are unclear. However, the largest series, which included 26 cases and was reported by Laskin , showed that although most patients were treated with wide excision, four developed distant metastases and three died of the disease within three years. High incidence of metastasis (seven of 14 cases) was also reported by Lodding in 1986 .
Aggressive surgery is considered the only procedure to improve prognosis of the MPNST [6, 7], and the response to chemotherapy against MPNST is poor according to previous reports ; however, several reports have demonstrated that chemotherapy can be effective [9, 10]. Although the standard regimens are still investigative, ifosfamide and doxorubicin are considered key drugs for advanced soft tissue sarcomas [11, 12]. In our clinical case, administering ifosfamide and doxorubicin with mesna showed good efficacy on the multiple lung metastases, with low-grade toxicities including myelosuppression and hair loss.
Surgical management of lung metastases may be effective in select situations . Two reports on MPNST demonstrated poor survival rates after development of pulmonary metastases, however; prolonged survived cases with thoracotomy were also described [7, 8]. As for nonosteogenic sarcoma, Creagan showed the overall 5-year survival following the first thoracotomy was 29% with a median survival of 18 months
. The present case involved the development of disseminating lung nodules ten weeks postoperatively, however; chemotherapy provided a favorable response to all metastatic lesions. Subsequently, thoracoscopic resection of the remaining three lesions was performed to both eliminate the sarcoma and allow histological evaluation of the response to chemotherapy. Based on the histological findings that two of the three lesions showed remaining sarcoma, continuing the same regimen without surgery may risk inducing development of chemotherapy-resistant sarcoma cells.
An extremely rare case of advanced EMPNST was reported. Multiple metastases to both lungs developed despite the adequately wide excision of the primary tumor. However, adjuvant chemotherapy and thoracoscopic resection yielded a favorable and complete response at the 12-month follow-up.
The authors declare that they have no competing interests
We appreciate the advice and expertise of Drs. Kensuke Oikawa and Koji Sakurai, pathologists at Asahikawa Kosei General Hospital. Gratitude is also expressed to the Departments of Pathology and Dermatology of Asahikawa Medical College for advice on histological diagnoses. We also thank Dr. Tetsuo Funai for performing thoracic surgery.
1. Weiss SW, Goldblum JR: Malignant tumors of the peripheral nerves. In Enzinger and Weiss’s Soft Tissue Tumors. 5th edition. Edited by Weiss SR, Goldblum JR. Philadelphia: Mosby Elsevier, pp.903-944, 2008.
2. Lodding P, Kindblom LG, Angervall L: Epithelioid malignant schwannoma. A study of 14 cases. Virchows Arch A Pathol Anat Histopathol, vol. 409, pp. 433-451, 1986.
3. Laskin WB, Weiss SW, Bratthauer GL: Epithelioid variant of malignant peripheral nerve sheath tumor (malignant epithelioid schwannoma). Am J Surg Pathol, vol. 15, pp. 1136-1145, 1991.
4. Manganoni AM, Farisoglio C, Lonati A, Zorzi F, Tucci G, Pinton PGC: Cutaneous epithelioid malignant schwannoma: review of the literature and case report. J Plast Reconstr Aesthet Surg, vol. 62, e318-e321, 2009.
5. Suster S, Amazon K, Rosen LB, Ollague JM: Malignant epithelioid schwannoma of the skin. A low-grade neurotropic malignant melanoma? Am J Dermatopathol, vol. 11, pp. 338-344, 1989.
6. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM: Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer, vol. 57, pp. 2006-2021, 1986.
7. Wanebo JE, Malik JM, Vandenberg SR, Wanebo HJ, Driesen N, Persing JA: Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases.
Cancer, vol. 71, pp. 1247-1253, 1993.
8. Sordillo PP, Helson L, Hajdu SI, Magill GB, Kosloff C, Golbey RB, Beattie EJ: Malignant schwannoma – clinical characteristics, survival, and response to therapy. Cancer, vol. 47, pp. 2503-2509, 1981.
9. Zambrana F, Vincente D, Garcia-Manrique T, Pereira S, De Zaitigui JS, Merino LDLC: Primary intracranial malignant peripheral nerve sheath tumour responding chemotherapy. Clin Transl Oncol, vol. 12, pp. 231-233, 2010.
10. Masui F, Yokoyama R, Soshi S, Beppu Y, Asanuma K, Fujii K: A malignant peripheral nerve-sheath tumour responding chemotherapy. J Bone Joint Surg [Br], vol. 86-B, pp. 113-115,2004.
11. Edmonson JH, Ryan LM, Blum RH, Brooks JSJ, Shiraki M, Frytak S, Parkinson DR: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol, vol. 11, pp. 1269-1275, 1993.
12. Goto T, Okuma T, Ogura K, Imanishi J, Hozumi T, Kondo T: Indication of chemotherapy according to histological type of musculoskeltal sarcomas. Jpn J Cancer Chemother, vol. 36, pp. 199-203, 2009.
13. Roth JA, Putnam JB, Wesley MN, Rosenberg SA: Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients. Cancer, vol. 55, pp. 1361-1366, 1985.
14. Creagan ET, Fleming TR, Edmonson JH, Pairolero PC: Pulmonary resection for metastatic nonosteogenic sarcoma. Cancer, vol. 44, pp. 1908-1912, 1979.
Figure 1: Preoperative view showing an enlarging mass in the third web space.
Figure 2: Preoperative positron emission tomography. (a) Abnormal uptake involving the affected foot. (b) No evidence of distant metastases.
Figure 3: Intraoperative views of ablative surgery and secondary reconstructive surgery. (a) Ipsilateral inguinal dissection at the first operation. (b) Wide excision of the primary lesion with a 30 mm surgical margin. (c) Free latissimus dorsi musculocutaneous flap transfer to the amputated stump.
Figure 4: Histological findings. (a) Proliferation of spindle cells with abnormal mitotic activities reminiscent of conventional malignant schwannoma (hematoxylin-eosin, × 400). (b) (c) Epithelioid features of round-to-polygonal or rhabdoid cells with cellular atypia resembling malignant melanoma (hematoxylin-eosin, × 400). (d) Immunohistochemical staining demonstrating strongly positive for S-100 protein.
Figure 5-7: Images of computed tomography at the same level of the lung respectively.
Figure 5: Ten weeks after the first operation. (a)(b) Development of multiple lung metastases (M1, M2, M3).
Figure 6: After two courses of adjuvant chemotherapy showing good response to all metastases. Note M3 was not recognizable.
Figure 7: Twelve months after the first operation. All metastatic lesions were eliminated through the chemotherapy and thoracic surgery.
Figure 8: Clinical view at 12-month postoperatively.
When you track a discussion, you will get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to track this discussion?
If you stop tracking this discussion, you will no longer get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to stop tracking this discussion?
Do you use smart phone apps?
Take our short survey on hospital smart phone apps.
We care about your feedback. Let us know how we can improve your CancerCompass experience.